VIVASOR, INC. – Trademark Portfolio
Entity Type: 03
VIVASOR, INC. holds 26 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 16 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 5 Nice Classification classes. Currently, 4 trademarks are registered and 8 are pending. Notable registered marks include SOFUSA and DOSECONNECT. The owner is based in SAN DIEGO, CA.
9380 JUDICIAL DRIVE
SAN DIEGO, CA 92121
Showing of trademarks Trademarks
Trademark Classifications
VIVASOR, INC.'s trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does VIVASOR, INC. have?
VIVASOR, INC. has 26 U.S. trademarks filed with the USPTO. Of these, 4 registered, 8 pending, 11 abandoned, 3 cancelled.
What trademark classes does VIVASOR, INC. file in?
VIVASOR, INC. files trademarks across 5 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 44 (Medical Services), Class 42 (Computer & Scientific), Class 10 (Medical Apparatus), Class 40 (Treatment & Processing). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are VIVASOR, INC.'s most well-known trademarks?
VIVASOR, INC.'s registered trademark portfolio includes well-known marks such as SOFUSA and DOSECONNECT. These are among 4 currently registered trademarks in the portfolio.
What is VIVASOR, INC.'s trademark registration success rate?
VIVASOR, INC. has a 22% trademark registration rate, with 4 out of 18 resolved applications resulting in successful registration. Currently, 8 applications are pending review.